An Oral Therapy With The Efficacy of A Biologic2
Xeljanz® demonstrated similar treatment effectiveness to biological DMARDS2
*P values are for one-sided noninferiority comparisons (98.34% confidence interval) and must be <0.025 to declare significance.2,3
ACR, American College of Rheumatology; BID, twice daily; IR, inadequate responders; LOCF, last observation carried forward; MTX, methotrexate; NRI, nonresponder imputation; NS, nonsignificant; q 2 wk, every 2 weeks; Sc, subcutaneous.
XELJANZ® (tofacitinib citrate) is a small molecule that selectively targets the JAK pathway
Review the upcoming events
These pages are not intended for patients or for members of the general public. The web pages contain promotional content.
If you select 'No', you will be redirected to Pfizer.co.in
For more details on, Who is a Registered Medical Practitioner*, please visit
https://cdsco.gov.in/opencms/export/sites/CDSCO_WEB/Pdf-documents/acts_rules/2016DrugsandCosmeticsAct1940Rules1945.pdf , Page No. 39, Rule 2 part (ee), last accessed on 13th September 2019.
Address: The Capital, A Wing, 1802, 18th Floor, Plot No. C-70, 'G' Block, Bandra Kurla Complex, Bandra East, Mumbai - 400051.
PP-UNP-IND-0012 July 2022